louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05215158: Intravenous Versus Peribulbar Dexmedetomidine for Strabismus Surgery in Adults
Official title: A Comparative Study of Intravenous Versus Peribulbar Administration of Dexmedetomidine for Strabismus Surgery in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Squint
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2022-01-31
Enrollment: 46
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Using various adjuvants has become a trend in regional anesthesia practice to improve the quality of anesthesia and prolong postoperative analgesia. Dexmedetomidine, an alpha-2 agonist has been proposed as a safe and effective adjunct capable of extending the duration of the single-shot block

Detailed description: Strabismus (misalignment of the eye) results from a difference in extraocular muscle function. Consequently, two different images, one from each eye, are transmitted to the brain, resulting in a loss of visual depth. In adults, cosmetic appearance is the main issue but sudden occurrence of strabismus may cause diplopia because the brain cannot suppress the overlapping images. The goal of strabismus surgery is to align the eyes, reduce diplopia, and restore binocular vision Ophthalmic regional block can be used as the primary anesthetic technique for strabismus surgery. The advantages of ophthalmic regional blockade include a reduced incidence of oculocardiac reflex (OCR) and emergence agitation, postoperative analgesia, and decreased postoperative nausea and vomiting (PONV).

Using various adjuvants has become a trend in regional anesthesia practice to improve the quality of anesthesia and prolong postoperative analgesia. Dexmedetomidine, an alpha-2 agonist has been proposed as a safe and effective adjunct capable of extending the duration of the single-shot block.

Perineural dexmedetomidine, when added to bupivacaine, has been shown to potentiate its effects, providing a better quality of anesthesia and postoperative analgesia. Intravenous (I.V.) dexmedetomidine, when used during regional anesthesia, has been shown to prolong sensory and motor blockade in addition to sedation and postoperative analgesia.

No previous studies where different routes of dexmedetomidine have been compared in adult strabismus surgery.

Eligibility criteria: Inclusion Criteria:

1. The patient planned to perform a unilateral strabismus surgery
2. Age: 20-60 years
3. American Society of Anesthesiologists class I and II

Exclusion Criteria:

1. patients under the age of 20
2. uncooperative patients
3. Patients with coagulopathy
4. patients who disincline to participate in the study will be excluded from the study

Primary outcomes:
measure: duration of analgesia
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
city: Aswan
country: Egypt
facility: Huda Fahmy
Study officials:
References:
Clinical trial NCT01390558: Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite
Official title: Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Down Syndrome
Keywords: Down Syndrome
Orthotics
Gait Analysis
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2011-07-11
Enrollment: 23
Sex: ALL
Minimum age (years): 2
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons with Down Syndrome followed in Down Syndrome clinic Persons with Down Syndrome recruited in the community

Brief summary: This is a research study of persons with Down Syndrome between 2 and 80 years old who are independently walking. The purpose of this study is to see what effect orthotics have on how people with Down Syndrome walk.


Eligibility criteria: Inclusion Criteria:

* Down Syndrome, independent walkers

Exclusion Criteria:

* Down Syndrome, not independently walking

Primary outcomes:
measure: Gait will be measured with the GaitRite gait evaluation system.
timeFrame: 3 years
Secondary outcomes:
measure: Elucidate patterns in the development of walking in persons with Down Syndrome using GaitRite®.
timeFrame: 3 years
Other outcomes:
Locations:
city: Portland
country: United States
facility: Child Development and Rehabilitation Center
state: Oregon
Study officials:
References:
Clinical trial NCT06552858: Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Official title: Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer: a Phase II Clinical Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Ovarian Cancer
Keywords: ovarian cancer
platinum resistance
Fluzoparib
Dalpiciclib
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2024-08-14
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.

Detailed description: 1. Overall Design: This trial is a single-center, prospective, single-arm, phase II clinical trial to evaluate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer.
2. Experimental observation indicators: 1) Main indicators: progression-free survival (PFS), 2) Other indicators: overall survival (OS), objective response rate (ORR), and adverse reactions.
3. Sample size calculation: The median PFS of platinum-resistant recurrent ovarian cancer patients is 3.8 months. In comparison, the experimental group is expected to have a median PFS of 7 months, with an alpha value of 0.05. Following up for 1 year and considering a 10% dropout rate, this study plans to include 30 platinum-resistant recurrent ovarian cancer patients.
4. Data Processing: Enter data and use SPSS statistical software for statistical analysis. Statistical analyst: Clinical Statistics Department of Fudan University Cancer Hospital. Mailing address: 270 Dong'an Road, Shanghai.

Eligibility criteria: Inclusion Criteria:

1. Age≥18 years old;
2. Sign the informed consent form;
3. Histologically-confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer.
4. Tumor recurrence or progression within 6 months after using platinum-based drugs;

Exclusion Criteria:

1. Any uncontrolled medical condition that may put the patient at high risk during treatment .
2. Receipt of any other investigational medicinal product within the last 30 days before randomization.
3. Patients with ovarian cancer excluded by pathological or clinical diagnosis;
4. Physical intolerance patients;
5. Patients who are unwilling to participate in the clinical trial.

Primary outcomes:
measure: PFS
timeFrame: Two years
Secondary outcomes:
measure: OS
timeFrame: Two years
measure: ORR
timeFrame: Two years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan university shanghai cancer center, Deparment of gynecologic oncology
state: Shanghai
Study officials:
References:
Clinical trial NCT05945758: Esthetic and Clinical Assessment of Injectable Resin Composite Technique
Official title: Esthetic and Clinical Assessment of Injectable Resin Composite Technique Compared to Conventional Layering Technique in Patients With Multiple Spacing in the Maxillary Anterior Teeth Area.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Clinical Performance
Keywords: injectable resin composite
conventional layering technique
FDI
multiple spacing
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-07-14
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: injectable resin composite technique will show a better clinical and esthetic performance compared to conventional layering resin composite technique in patients with multiple spacing in the maxillary anterior teeth area or not.

Detailed description: The injectable composite resin technique is an indirect/direct method that uses a transparent silicone index for accurate and predictable translation of diagnostic wax-up into composite restorations without the need for tooth preparation. The injection molding technique has the advantage of replicating the excellent anatomy defined by a lab-made diagnostic wax-up whereby it would be used for the fabrication of direct restorations, so excellent anatomy results, verifies aesthetics, phonetics, and occlusion, avoids misunderstandings, as it is easy to implement and repair.

Eligibility criteria: Inclusion Criteria:

* Sound and vital upper anterior teeth.
* Spacing in the maxillary anterior teeth area ranging from .5mm to 2mm.
* Minor misalignment, correction of peg laterals.

Exclusion Criteria:

* Non-vital, fractured, or cracked teeth.
* Teeth with caries or in need of replacement of existing restorations.
* Rampant caries, atypical extrinsic staining of teeth.
* Heavy occlusion and occlusal contacts or history of bruxism.
* Severe periodontal affection.

Primary outcomes:
measure: Change from baseline in Esthetic anatomical form at 6,12,18& 24 months.
timeFrame: T1: Baseline. T2: 6 months. T3: 12 months. T4: 18 months. T5: 24 months.
Secondary outcomes:
measure: Change from baseline in Color match and translucency at 6,12,18& 24 months.
timeFrame: T1: Baseline. T2: 6 months. T3: 12 months. T4: 18 months. T5: 24 months.
measure: Change from baseline in Surface and marginal staining at 6,12,18& 24 months.
timeFrame: T1: Baseline. T2: 6 months. T3: 12 months. T4: 18 months. T5: 24 months.
measure: Change from baseline in Surface lustrous at 6,12,18& 24 months.
timeFrame: T1: Baseline. T2: 6 months. T3: 12 months. T4: 18 months. T5: 24 months.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06555458: The Effect of Sedation on Rebound Pain in Knee Arthroplasty
Official title: The Effect of Sedation on Rebound Pain in Knee Arthrplasty Performed Under Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Total Knee Arthroplasty
Sedation
Lead sponsor: Ankara City Hospital Bilkent
Sponsor class: OTHER
First posted: 2024-08-15
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Dexmedetomidine is often used for sedation procedures. It has also been shown to have a pain-protective effect. Researchers predicted that using dexmedetomidine for sedation in total knee arthroplasties performed under spinal anesthesia would reduce the frequency of rebound pain and pain scores.

Detailed description: Randomization will take place before the patient enters the operating room. After spinal anesthesia is applied, 0.4 mcg/kg sedadomide loading will be done for 10 minutes in the sedation group, and then 0.4 mcg/kg/h sedadomide infusion will continue until the end of the surgery. Patients selected for the control group will be given the same amounts of saline. At the end of the surgical procedure, saline and sedadomide infusions will be stopped. All patients will undergo an adductor canal block under USG guidance in the recovery room. 50 mg of buvacin will be given to the block area. Patients will be fitted with a patient control analgesia device, which only provides bolus application and provides 20 mg of madol in each bolus. Postoperatively, sudden onset severe withdrawal pain outside the normal course of pain starting within 48 hours will be followed and Vas-bromage monitoring will be done at 0, 1, 2, 4, 8, 12, 24, 36, 48 hours.

Eligibility criteria: Inclusion Criteria:

* Total Knee arthroplasty American Society of Anesthesiologist score of 1-3 Age 18-85 Elective total knee arthroplasty under spinal anesthetic.

Exclusion Criteria:

* Situations in which spinal anesthesia is contraindicated
* Advanced organ failure states(cardiac,hepatic,respiratuar or renal)
* Pregnancy
* BMI \> 40 kg/m\^2
* Do not want to participate in the study
* Younger than 18 or older than 85
* Have bilateral total knee arthroplasty or resurgery
* Develop an unexpected intraoperative surgical complication

Primary outcomes:
measure: Rebound pain VAS scores and incidence of rebound pain
timeFrame: 48 hours after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Bilkent City Hospital
state: Çankaya
Study officials:
References:
Clinical trial NCT02765958: Analyze Sleep Stages by Portable ECG Device
Official title: Analyze Sleep Stages by Portable ECG Device
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obstructive Sleep Apnea
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2016-05-09
Enrollment: 35
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: outpatient in chest clinic

Brief summary: Sleep is a fundamental need for human and is associated with the working performance and the disease occurrence. Furthermore, the amount of people with sleep disorder or apnea increased largely. Thus, the analysis of sleep stages and the measurement of sleep quality became more important recently. In clinical settings, the analysis of daily sleep quality depends on actigraphy and sleep log. However, the uses of actigraphy and sleep log are not really convenient for patients. In this trial, the investigators will measure the subjects' ECG signal and movement using a portable ECG device with motion sensor. On the other hand, the sleep stages are also obtained from the current wide-established measurement- polysomnography. The ECG signals, movements, and sleep stages will be analyzed by our algorithm of artificial neural network. Then, the investigators can obtain the preliminary analysis of sleep quality can be obtained by using ECG device with our algorithm. It is helpful for doctors to realize the patent's sleep quality quickly


Eligibility criteria: Inclusion Criteria:

* OSA: OPD OSA patients; Healthy: no OSA

Exclusion Criteria:

* heart disease
* arrhythmia

Primary outcomes:
measure: RR interval changes compared to the report of polysomography
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
city: New Taipei
country: Taiwan
facility: Far Eastern Memorial Hospital
Study officials:
affiliation: Far Eastern Memeorial Hospital
name: Ping-huai Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05706558: Retrospective Review of Esophageal Cancer at MSKCC
Official title: Retrospective Review of Esophageal Cancer at MSKCC
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Esophageal Cancer
Esophagus Cancer
Keywords: Esophageal Cancer
Esophagus Cancer
Memorial Sloan Kettering Cancer Center
16-1631
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2023-01-31
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants undergoing esophagectomy for histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) during the period from 2000 to 2019.

Brief summary: Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
* Pathologic staged T3 tumors (pT3)

Exclusion Criteria:

* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
* Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
* Patients undergoing salvage esophagectomy
* Evidence of distant metastatic disease
* Patients with a positive proximal or distal margin

Primary outcomes:
measure: . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
timeFrame: Up to 2 years
Secondary outcomes:
measure: Overall survival and progression-free survival (measured from date of surgery)
timeFrame: Up to 2 years
measure: Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).
timeFrame: Up to 2 years
measure: Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).
timeFrame: Up to 2 years
measure: Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Daniela Molena, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06916858: Prevalence of Obstructive Sleep Apnea and Accuracy of Type 3 Home Sleep Apnea Test for Obstructive Sleep Apnea Diagnosis in Difficult-to-treat Asthma
Official title: Prevalence of Obstructive Sleep Apnea and Accuracy of Type 3 Home Sleep Apnea Test for Obstructive Sleep Apnea Diagnosis in Difficult-to-treat Asthma: Cross Sectional Cohort Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Difficult-to-treat Asthma, Underwent Type 1 In-laboratory Polysomnography and Type 3 HSAT Within 1 Month Apart
Keywords: asthma
OSA
HSAT
home sleep test
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2025-04-08
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: cross sectional cohort study enroll Patients diagnosed with difficult-to-treat asthma, aged over 18 years, and experiencing persistent symptoms as assessed by the Asthma Control Test (ACT) underwent type 1 in-laboratory polysomnography and type 3 HSAT within 1 month apart


Eligibility criteria: Inclusion Criteria:

* difficult-to-treat asthma .
* Patients aged 18 years or older

Exclusion Criteria:

* Patients or volunteers unable to undergo type 1 and type 3 sleep studies,
* Patients with symptoms compatible with other sleep disorders,
* Patients with a history of or current stroke or transient ischemic attack and Other chronic respiratory diseases.
* Patients diagnosed with obstructive sleep apnea

Primary outcomes:
measure: prevalence of OSA in patients with difficult-to-treat asthma
timeFrame: up to 4 months
Secondary outcomes:
measure: assess the accuracy of type 3 home sleep apnea test (HSAT)
timeFrame: up to 1 months
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Tidarat Somreusean
Study officials:
References:
Clinical trial NCT05261958: Effect of Speed,Agility and Quickness Training on Technical Skills in Football Players
Official title: Effect of Speed, Agility and Quickness Training on Technical Skills in Football Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Fitness
Keywords: Football, Technical skills, speed, agility, quickness
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2022-03-02
Enrollment: 50
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups with randomization Assignment: High knee with mini hurdles, agility ring hops, 30 yard sprint, depth jumps, overhead ball drop
Primary purpose: OTHER

Brief summary: The study is designed to determine the effectiveness of Speed, Agility and Quickness training on technical skills in football players

Detailed description: Football is a fast-paced, dynamic sport that requires expert movements. The goal of the game is to outscore your opponent in terms of goals scored. Players must perform a variety of expert movements, both with and without the ball, to achieve this goal. 'The learned ability to bring about predetermined results with utmost assurance, frequently with the least investment of time or energy or both,' according to an initial definition of talent. 'The constant output of goal-oriented movements, which are taught and unique to the job,' according to a more modern definition of competence. It is critical for players to have the fundamental motor abilities, such as running, agility, and acceleration, in order to learn and execute soccer skills effectively. Fundamental motor skills are seen as essential precursors or related factors to technical skills and therefore excellence in soccer.Furthermore, through a variety of soccer-specific activities, the SAQ training system consolidates speed, agility, and quickness. All exercises are carried out with appropriate biomechanical movement structures, resulting in significant energy and time savings. Aside from major abilities, power performance necessitates optimal joint mobility, dynamic balance, an appropriate locomotors system, and energy generation, among other things.

Eligibility criteria: Inclusion Criteria:

* Male players
* Age group of 18 years to 25 years.
* The study includes players, who are playing form 6 months to 1 year.

Exclusion Criteria:

* Players with any disability
* Injured players
* Players with psychological issues
* Players who are on any sort of medication

Primary outcomes:
measure: Shuttle Run test
timeFrame: 6 weeks
measure: 12 min run test
timeFrame: 6 weeks
measure: Speed
timeFrame: 6 weeks
measure: Vertical jump
timeFrame: 6 weeks
measure: Mcdonald Soccer skill test
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Riphah international University
state: ICT
Study officials:
affiliation: Riphah International University
name: Waqar Ahmed Awan, PhD
role: PRINCIPAL_INVESTIGATOR
References: